ReviewFrontiers in pharmacology2022
Natural Products from Actinobacteria as a Potential Source of New Therapies Against Colorectal Cancer: A Review.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Anticancer Potential of Streptomyces sp. Strain M12: Apoptosis Induction and Anti-Migratory Effects in Colorectal Cancer Cells.Applied biochemistry and biotechnology · 2026Article
- Investigation of Transcriptome and Kinome in Non Metastatic and Metastatic Renal Clear Cancer Stem Cells and Their Relationship with Gut Microbiota.Molecular biotechnology · 2026Article
- Exploring the anticancer potential of Streptomyces sp. M4 extract: effects on apoptosis in gastric cancer ags cells.Folia microbiologica · 2026Article
- A novel Umezawaea tangerina endophyte reveals anti-colorectal cancer activity and a rich biosynthetic landscape.Scientific reports · 2026Article
- Microbial Landscape of Bull (Animals : an open access journal from MDPI · 2026Article
- Questiomycin A demonstrates antibacterial activity against Mycobacterium tuberculosis by directly targeting FabD.Communications biology · 2026Article
- Taxonomic descriptions of Nocardia anocheti sp. nov. and Streptomyces odontomachicola sp. nov. isolated from ants.Scientific reports · 2026Article
- Harnessing the microbiome: unveiling the influence of the gut microbiota on hepatobiliary cancer therapeutic strategies.Clinical and molecular hepatology · 2026Review
- Uncovering antioxidant and anti-breast cancer potential metabolite fromFrontiers in pharmacology · 2026Article
- Microbial-Derived Anti-Cancer Compounds: Advances in Drug Discovery, Bioengineering, and Therapeutic Applications.Anti-cancer agents in medicinal chemistry · 2026Review
- Article
- GC-MS Profiling and In Silico Pathway Mapping of Brevibacterium casei VRK 1 Metabolites for exploring Anti-inflammatory and Antioxidant Activities.Applied biochemistry and biotechnology · 2025Article
- Review
- Endophytic actinobacteria from Mentha longifolia and Lonicera nummulariifolia: a novel source against antibiotic resistance.BMC microbiology · 2025Article
- Discovery and Heterologous Expression of Trilenodin, an Antimicrobial Lasso Peptide with a Unique Tri-Isoleucine Motif.Chembiochem : a European journal of chemical biology · 2024Article
- Exploring Bioactive Potential ofIndian journal of microbiology · 2024Article
- In-vitro antibacterial and antibiofilm activities and in-silico analysis of a potent cyclic peptide from a novel Streptomyces sp. strain RG-5 against antibiotic-resistant and biofilm-forming pathogenic bacteria.Archives of microbiology · 2024Article
- Harnessing bacterial metabolites for enhanced cancer chemotherapy: unveiling unique therapeutic potentials.Archives of microbiology · 2024Review
- What is the role of microbial biotechnology and genetic engineering in medicine?MicrobiologyOpen · 2024Review
- GPX2 acts as an oncogene and cudraflavone C has an anti-tumor effect by suppressing GPX2-dependent Wnt/β-catenin pathway in colorectal cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a common, and deadly disease. Despite the improved knowledge on CRC heterogeneity and advances in the medical sciences, there is still an urgent need to cope with the challenges and side effects of common treatments for the disease. Natural products (NPs) have always been of interest for the development of new medicines. Actinobacteria are known to be prolific producers of a wide range of bioactive NPs, and scientific evidence highlights their important protective role against CRC. This review is a holistic picture on actinobacter-derived cytotoxic compounds against CRC that provides a good perspective for drug development and design in near future. This review also describes the chemical structure of 232 NPs presenting anti-CRC activity with the being majority of quinones, lactones, alkaloids, peptides, and glycosides. The study reveals that most of these NPs are derived from marine actinobacteria followed by terrestrial and endophytic actinobacteria, respectively. They are predominantly produced by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.